Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 15/20 | 1.00 |
| ▸ | IL1B | P01584 | 2/20 | 0.69 |
| ▸ | CASP8 | Q14790 | 3/20 | 0.64 |
| ▸ | CASP3 | P42574 | 2/20 | 0.64 |
| ▸ | LCK | P06239 | 4/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vrt-18858 SCHEMBL647044 | 1.00 | CASP1 (1.00) | CASP1IL1BCASP8CASP3LCK | |
| Vrt-18858 SCHEMBL30070800 | 1.00 | CASP1 (1.00) | CASP1IL1BCASP8CASP3LCK | |
| SCHEMBL16883405 | 0.94 | CASP1 (0.88) | CASP1IL1BCASP8CASP3LCK | |
| SCHEMBL10200428 | 0.94 | CASP1 (0.88) | CASP1IL1BCASP8CASP3LCK | |
| SCHEMBL2364341 | 0.90 | CASP1 (0.81) | CASP1IL1BCASP8CASP3LCK | |
| SCHEMBL8284807 | 0.88 | CASP1 (0.79) | CASP1IL1BCASP8CASP3LCK | |
| SCHEMBL647338 | 0.88 | CASP1 (0.80) | CASP1IL1BCASP8CASP3LCK | |
| SCHEMBL1414699 | 0.88 | CASP1 (0.80) | CASP1IL1BCASP8CASP3LCK | |
| SCHEMBL10199776 | 0.88 | CASP1 (0.78) | CASP1IL1BCASP8CASP3LCK | |
| SCHEMBL10199411 | 0.87 | CASP1 (0.77) | CASP1IL1BCASP8CASP3LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310412-A1 | USE OF CASPASE INHIBITOR FOR ALLEVIATING OR TREATING OSTEOARTHRITIS | LG CHEM, LTD. (KR) | 2023-10-05 | — | — | US | disclosed |
| US-20230310412-A1 | USE OF CASPASE INHIBITOR FOR ALLEVIATING OR TREATING OSTEOARTHRITIS | LG CHEM, LTD. (KR) | 2023-10-05 | — | — | US | disclosed |
| US-9956260-B1 | Treatment of HIV-1 infection and AIDS | THE J. DAVID GLADSTONE INSTITUTES (US) | 2018-05-01 | — | — | US | disclosed |
| US-9956260-B1 | Treatment of HIV-1 infection and AIDS | THE J. DAVID GLADSTONE INSTITUTES (US) | 2018-05-01 | — | — | US | disclosed |
| US-9352010-B2 | Treatment of HIV-1 infection and AIDS | THE J. DAVID GLADSTONE INSTITUTES (US) | 2016-05-31 | — | — | US | disclosed |
| US-9352010-B2 | Treatment of HIV-1 infection and AIDS | THE J. DAVID GLADSTONE INSTITUTES (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160008420-A1 | Treatment Of HIV-1 Infection And AIDS | THE J. DAVID GLADSTONE INSTITUTES | 2016-01-14 | — | — | US | disclosed |
| US-20160008420-A1 | Treatment Of HIV-1 Infection And AIDS | THE J. DAVID GLADSTONE INSTITUTES | 2016-01-14 | — | — | US | disclosed |
| US-20150343011-A1 | Treatment Of HIV-1 Infection And AIDS | THE J. DAVID GLADSTONE INSTITUTES | 2015-12-03 | — | — | US | disclosed |
| US-20150343011-A1 | Treatment Of HIV-1 Infection And AIDS | THE J. DAVID GLADSTONE INSTITUTES | 2015-12-03 | — | — | US | disclosed |
| US-7790713-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790713-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790713-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2083014-A2 | Inhibitors of interleukin-1ß converting enzyme | Vertex Pharmceuticals Incorporated (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20080279934-A1 | EXTENDED RELEASE FORMULATION FOR PRALNACASAN | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
| US-20080039449-A1 | Inhibitors of interleukin-1beta converting enzyme | BATCHELOR MARK J | 2008-02-14 | — | — | US | disclosed |
| US-20080039449-A1 | Inhibitors of interleukin-1beta converting enzyme | BATCHELOR MARK J | 2008-02-14 | — | — | US | disclosed |
| WO-2005117846-A2 | ICE INHIBITORS FOR THE TREATMENT OF AUTOINFLAMMATORY DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005053665-A1 | TREATING INFECTIOUS DISEASES USING ICE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-06-16 | — | — | WO | disclosed |
| US-6258948-B1 | AN N-ACYLAMINO COMPOUND; ANTIINFLAMMATORY AGENTS, AUTOIMMUNE DISEASES | VERTEX PHARMACEUTICALS, INCORPORATED | 2001-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310412-A1 | USE OF CASPASE INHIBITOR FOR ALLEVIATING OR TREATING OSTEOARTHRITIS | CASP1, CASP2, CASP5 | CASP1 1/4885IL1B 117/4885CASP8 11/4885 |
| US-20150343011-A1 | Treatment Of HIV-1 Infection And AIDS | CD4, CASP1, PYCARD | CASP1 2/4885IL1B 30/4885CASP8 7/4885 |
| US-20160008420-A1 | Treatment Of HIV-1 Infection And AIDS | CD4, CASP1, PYCARD | CASP1 2/4885IL1B 30/4885CASP8 7/4885 |
| US-20080039449-A1 | Inhibitors of interleukin-1beta converting enzyme | IL1A, IL1B, IFNAR1 | CASP1 5/4885IL1B 2/4885CASP8 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.